Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced the appointment of James Gruber as Chief Financial Officer, effective immediately, following the retirement of Wilson Troutman. Mr. Troutman will assist in the transition until the end of May. Gruber brings over 20 years of financial experience, including a significant tenure at Horizon Therapeutics where he managed financial operations during substantial growth. Eton, focused on rare disease treatments, currently owns or earns royalties from seven FDA-approved products and has three additional submissions pending.

Positive

• James Gruber's extensive experience in managing financial activities, particularly during periods of rapid growth, is expected to enhance Eton's financial operations.
• Recent commercial product launches signify a promising growth trajectory for Eton Pharmaceuticals.

Negative

• Transitioning CFOs can introduce operational risks if the incoming CFO cannot align with current strategies.
• Potential gaps in continuity following Wilson Troutman's retirement may affect investor confidence.

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition.

“We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we enter the next stage of our evolution as a rapidly growing commercial company,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

“On behalf of everyone at Eton, I want to thank Wilson for his dedicated service to the company and congratulate him on a well-deserved retirement. Wilson has been instrumental to the company since its inception in 2017. His contributions to the company were both positive and impactful over the years. Although we are sad to see him go, we wish him all the best in his retirement,“ added Brynjelsen.

“I am excited to be joining Eton. It is a terrific opportunity to join a company that is extremely well positioned with so many ongoing and near-term commercial product launches. I look forward to working with the team to continue building a leading pharmaceutical company,” said James Gruber.

Mr. Gruber brings more than 20 years of financial and accounting experience to Eton. Most recently, he was the U.S. Controller at Horizon Therapeutics for seven years, where he oversaw accounting activities for the company during its rapid growth. During Mr. Gruber’s tenure at Horizon, the company closed and integrated multiple acquisitions, launched new products, and saw its revenue increase more than 10-fold. Prior to Horizon, Mr. Gruber spent 14 years at Abbott Laboratories where he held various financial and accounting leadership positions. Mr. Gruber holds an M.B.A from Northwestern University’s Kellogg School of Management, a B.S in accounting from Indiana University, and is a Certified Public Accountant.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from seven FDA-approved products, including ALKINDI SPRINKLE^®, Carglumic Acid, Biorphen^®, Alaway^® Preservative Free, Rezipres^®, Eprontia™, and cysteine injection and has three additional products that have been submitted to the FDA.

Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740

FAQ

Who is the new CFO of Eton Pharmaceuticals?

James Gruber has been appointed as the Chief Financial Officer of Eton Pharmaceuticals.

What was Wilson Troutman's role at Eton Pharmaceuticals?

Wilson Troutman served as the Chief Financial Officer prior to his retirement.

What experience does James Gruber bring to Eton Pharmaceuticals?

James Gruber brings over 20 years of financial experience, including significant roles at Horizon Therapeutics and Abbott Laboratories.

What impact might the CFO transition have on Eton Pharmaceuticals?

The transition could introduce operational risks and affect investor confidence, especially if continuity in financial strategy is not maintained.

How many FDA-approved products does Eton Pharmaceuticals currently have?

Eton Pharmaceuticals owns or receives royalties from seven FDA-approved products.